Plus Therapeutics, Inc. to Present at The LD 500 Virtual Conference
August 28 2020 - 6:00AM
Plus Therapeutics, Inc (Exchange: PSTV) , today announced that it
will be presenting at the LD 500 investor conference on Friday,
September 4 at 10.20 AM ET. Dr. Marc Hedrick, President and CEO of
Plus Therapeutics, will be hosting the presentation and answering
questions from investors.
Register here: https://ld500.ldmicro.com/
"We have been waiting for this moment all year long. Due to
COVID, it has been nearly impossible for physical conferences to
even take place. I want to show the world that you can still learn,
have a great time, and see some of the most unique companies in the
capital markets today. All without having to step foot outside. For
the first time, LD Micro is accessible to everyone, and we are
honored to welcome you to one of the most trusted platforms in the
space,” stated Chris Lahiji, Founder of LD.
The LD 500 will take place on September 1st through the 4th.
View Plus Therapeutics’ profile here:
http://www.ldmicro.com/profile/PSTV
Profiles powered by LD
Micro — News Compliments
of Globe Newswire
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage
pharmaceutical company whose radiotherapeutic portfolio is
concentrated on nanoliposome-encapsulated radionucleotides for
several cancer targets. Central to the Company’s drug development
is a unique nanotechnology platform designed to reformulate,
deliver and commercialize multiple drugs targeting rare cancers and
other diseases. The platform is designed to facilitate new delivery
approaches and/or formulations of safe and effective, injectable
drugs, potentially enhancing the safety, efficacy and convenience
for patients and healthcare providers. More information may be
found at www.plustherapeutics.com and at
www.respect-trials.com.
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an
independent resource to the microcap world.
What started as a newsletter highlighting unique companies, has
transformed into the pre-eminent event platform in the space.
The upcoming "500" in September is the Company's most ambitious
project yet, and the first event that is accessible to
everyone.
For those interested in attending, please contact David Scher at
david@ldmicro.com or visit www.ldmicro.com for more
information.
Contact:
Plus Therapeutics, Inc. Andrew Sims VP –
Chief Financial Officer, Investor Relations Phone: +1.619.333.4150
Email: ir@plustherapeutics.com Corporate
Website: plustherapeutics.comClinical Website:
respect-trials.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2024 to May 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From May 2023 to May 2024